The Safety of Finerenone in Patients with Chronic Kidney Disease during Ramadan Fasting

• DOI: 10.1055/s-0044-1801821
• Publication Date: 2025-04-01T23:51:39Z
• Authors: Bachar Afandi; Fatima Alkindi; Yousef Boobes; Latifa Baynouna A...; Nico Nagelkerke

Abstract Introduction Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, is used in the management of chronic kidney disease (CKD) patients with type 2 diabetes mellitus and albuminuria. However, safety finerenone during Ramadan fasting has not been evaluated previously. This study aims to evaluate clinical outcomes use this group. Patients Methods retrospective cohort was conducted at Tawam Hospital Ambulatory Healthcare Services, United Arab Emirates, from July 2023 2024. The included on therapy compared them control group using finerenone. were further subdivided into nonfasting groups. Baseline, Ramadan, post-Ramadan laboratory data analyzed, including glycemic (hemoglobin A1c [HbA1c]) renal function (estimated glomerular filtration rate [eGFR]). To assess adverse events, descriptive regression analyses performed. Results A total 42 finerenone-treated 271 controls. had higher rates CKD proteinuria multiple antidiabetic medications. Among who observed fasting, decline eGFR decrease HbA1c Hypoglycemia significantly (36.7%) than non-finerenone (13%). Finerenone stage significant predictors events. Conclusion Our highlights potential risks associated hypoglycemia decline. These findings emphasize need for careful patient selection, individualized treatment adjustments, close monitoring. Larger, prospective studies are needed validate these observations provide definitive guidance.